Ezpeleta, G.; Navascués, A.; Viguria, N.; Herranz-Aguirre, M.; Juan Belloc, S.E.; Gimeno Ballester, J.; Muruzábal, J.C.; GarcÃa-Cenoz, M.; Trobajo-SanmartÃn, C.; Echeverria, A.;
et al. Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study. Vaccines 2024, 12, 383.
https://doi.org/10.3390/vaccines12040383
AMA Style
Ezpeleta G, Navascués A, Viguria N, Herranz-Aguirre M, Juan Belloc SE, Gimeno Ballester J, Muruzábal JC, GarcÃa-Cenoz M, Trobajo-SanmartÃn C, Echeverria A,
et al. Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study. Vaccines. 2024; 12(4):383.
https://doi.org/10.3390/vaccines12040383
Chicago/Turabian Style
Ezpeleta, Guillermo, Ana Navascués, Natividad Viguria, Mercedes Herranz-Aguirre, Sergio Enrique Juan Belloc, Juan Gimeno Ballester, Juan Carlos Muruzábal, Manuel GarcÃa-Cenoz, Camino Trobajo-SanmartÃn, Aitziber Echeverria,
and et al. 2024. "Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study" Vaccines 12, no. 4: 383.
https://doi.org/10.3390/vaccines12040383
APA Style
Ezpeleta, G., Navascués, A., Viguria, N., Herranz-Aguirre, M., Juan Belloc, S. E., Gimeno Ballester, J., Muruzábal, J. C., GarcÃa-Cenoz, M., Trobajo-SanmartÃn, C., Echeverria, A., MartÃnez-Baz, I., Vera-Punzano, N., Casado, I., López-Mendoza, H., Ezpeleta, C., & Castilla, J.
(2024). Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study. Vaccines, 12(4), 383.
https://doi.org/10.3390/vaccines12040383
